Table 1 Baseline characteristics of the study population
Patient characteristics | All N = 41 | STEMI n = 32 (78%) | NSTEMI n = 9 (22%) | P-value |
|---|---|---|---|---|
age | 56 ± 8 | 56 ± 8 | 55 ± 8 | 0.8 |
sex | 3:38 (F:M) | 2:30 (F:M) | 1:8 (F:M) | Â |
Risk Factors [No (%)] | Â | Â | Â | Â |
Smoking | 14 (35) | 13 (40) | 1 (11) | 0.13 |
Hypertension | 15 (37) | 9 (28) | 7 (78) | 0.17 |
Diabetes | 4 (10) | 1 (3) | 3 (34) | 0.03 |
Family history | 15 (37) | 12(37) | 3 (34) | 1.0 |
Hyperlipidemia | 16 (40) | 10 (31) | 5 (56) | 0.25 |
Previous angina | 4 | 2 | 2 | 0.2 |
Presenting characteristics | Â | Â | Â | Â |
Troponin I (12 hours post admission) (mg/mL) | 32 ± 20 | 38 ± 15 | 9 ± 7 | < 0.01 |
Median (IQR) Time from onset of symptoms to procedure (hrs) | 3 (2.2, 9) | 2.6 (2.0, 4.2) | 24(13, 36) | 0.0001 |
Culprit coronary artery [No (%)] | Â | Â | Â | Â |
LAD | 21 (52) | 17(53) | 4 (44) | 1.0 |
LCx | 4 (10) | 2 (6) | 2 (22) | 0.3 |
RCA | 17 (42) | 14 (40) | 3 (33) | 0.15 |
N of vessel diseased, n (%) | Â | Â | Â | Â |
0 | 1 | 0 | 1 | 0.22 |
1 | 25 (61) | 24 (75) | 1 (11) | 0.001 |
2 | 7 (17) | 5 (16) | 3 (33) | 0.3 |
3 | 7 (17) | 3 (9) | 4 (45) | 0.03 |
Drug therapy n (%) | Â | Â | Â | Â |
Aspirin | 41 (100) | 32 (100) | 9 (100) | 1 |
Glycoprotein IIb/IIIa inhibitor | 33 (80) | 32 (100) | 1 (11) | < 0.001 |
Clopidogrel | 41(100) | 32 (100) | 9 (100) | 1 |
β-Blockers | 41 (100) | 32 (100) | 9 (100) | 1 |
Heparin | 41 (100) | 32 (100) | 9 (100) | 1 |